Skip to main content
TipRanks
Go Ultimate75% OFF

KYORIN Pharmaceutical Co.,Ltd. (4569) AI Stock Analysis

3 Followers
JP:4569

KYORIN Pharmaceutical Co.,Ltd.

(TSE/TYO:4569)

Select Model
Rating:46Neutral
Price Target:JPY 1,095.00â–²(0.74% Upside)
Action:reiterated
Date:11/18/26

KYORIN Pharmaceutical scores poorly overall, driven primarily by weak financial performance. Despite a conservatively managed, low-leverage balance sheet, profitability is thin and deteriorating, with FY2026 projections pointing to revenue contraction, a sharp margin squeeze, and a roughly 62% fall in net income. Cash flow generation is unreliable, with three straight years of negative free cash flow. Technically, the stock remains in a longer-term downtrend well below its 200-day moving average with negative MACD, though it has begun to stabilize around its short-term averages. Valuation offers little support: a 165x P/E reflects depressed earnings, and while the 4.2% dividend yield is appealing, its durability is uncertain given weak cash generation. The low beta of 0.45 provides some defensive cushion, but it does not offset the fundamental deterioration.

Positive Factors
Low financial leverageConservative leverage gives KYORIN financial flexibility to sustain pharmaceutical investment and absorb earnings volatility without heavy debt pressure. The consistently low debt-to-equity profile also reduces refinancing exposure and leaves more room for future capital allocation.
Negative Factors
Material profitability deteriorationThe sharp FY2026 margin compression shows that earnings are currently more sensitive to cost or product mix pressure. Unless profitability recovers, weaker margins can reduce internal funding for research, commercial investment, and shareholder returns over the next several quarters.

KYORIN Pharmaceutical Co.,Ltd. (4569) vs. iShares MSCI Japan ETF (EWJ)

-30%-20%-10%0%10%20%30%JP:4569-24.03%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 57.64B
Dividend Yield
4.32%
Average Volume (3M)
205.24K
Price to Earnings (P/E)
160.8
Beta (1Y)
0.40
Revenue Growth
-6.48%
EPS Growth
-95.83%
Country
Japan
Employees
1,982
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

KYORIN Pharmaceutical Co.,Ltd. Business Overview & Revenue Model

Company Description

Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse...

KYORIN Pharmaceutical Co.,Ltd. Financial Statement Overview

Summary

Financials are mixed-to-weak. The balance sheet is the clear strength (score 68), with low debt-to-equity of 0.16–0.21, steadily growing assets and equity, though ROE of just 3.2%–6.7% signals poor capital efficiency. The income statement (score 42) shows solid multi-year revenue growth to ¥130.1B in FY2025, but gross margins have eroded from ~50% to ~46%, and FY2026 guidance implies a ~4.3% revenue decline, a collapse in EBIT margin to ~2.8%, and a ~62% drop in net income. Cash flow is the weakest link (score 35), with volatile operating cash flow and three consecutive years of negative free cash flow through FY2025, raising earnings-quality and self-funding concerns.

Income Statement

42Neutral

Balance Sheet

68Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue125.02B126.26B130.09B119.53B113.27B105.53B
Gross Profit49.10B51.61B59.51B51.62B50.16B49.44B
EBITDA7.19B8.22B17.15B10.52B8.96B8.72B
Net Income388.00M3.45B9.09B5.47B4.72B3.93B
Balance Sheet
Total Assets186.82B195.46B193.62B177.63B176.04B171.92B
Cash, Cash Equivalents and Short-Term Investments23.24B15.08B16.51B13.98B19.39B27.49B
Total Debt23.17B23.79B28.44B20.95B21.28B21.62B
Total Liabilities48.76B53.02B57.33B46.89B50.58B47.41B
Stockholders Equity138.06B142.43B136.28B130.74B125.46B124.51B
Cash Flow
Free Cash Flow02.52B-2.19B-4.23B-4.32B3.90B
Operating Cash Flow06.38B3.51B1.55B2.01B6.35B
Investing Cash Flow0-1.64B-6.32B-3.19B-6.28B-2.56B
Financing Cash Flow0-7.96B3.95B-3.35B-3.36B-4.11B

KYORIN Pharmaceutical Co.,Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price1087.00

Price Trends

50DMA1097.95Negative
100DMA1122.50Negative
200DMA1304.63Negative

Market Momentum

MACD-1.80Negative
RSI47.31Neutral
STOCH61.88Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4569, the sentiment is Negative. The current price of 1087.00 is below the 20-day moving average (MA) of 1099.60, below the 50-day MA of 1097.95, and below the 200-day MA of 1304.63, indicating a bearish trend. The MACD of -1.80 indicates Negative momentum. The RSI at 47.31 is Neutral, neither overbought nor oversold. The STOCH value of 61.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4569.

KYORIN Pharmaceutical Co.,Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4569 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4516JP:451674OutperformJPY 222.40B7.56―3.76%17.69%-7.87%
JP:4534JP:453473OutperformJPY 114.51B11.067.68%2.45%15.85%60.55%
JP:4547JP:454773OutperformJPY 178.50B16.214.95%4.69%5.87%-21.16%
JP:4521JP:452153NeutralJPY 137.05B15.746.11%4.99%5.43%1167.62%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4553JP:455350NeutralJPY 160.44B41.132.10%2.45%7.06%-81.10%
JP:4569JP:456946NeutralJPY 57.22B160.80―4.32%-6.48%-95.83%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%60%JP:4569JP:4521JP:4547JP:4553JP:4534JP:4516Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4569 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4569KYORIN Pharmaceutical Co.,Ltd.1087.00-348.63-24.28%
JP:4521Kaken Pharmaceutical Co 3805.00189.535.24%
JP:4547Kissei Pharmaceutical Co 4370.0035.730.82%
JP:4553Towa Pharmaceutical Co 3260.00188.496.14%
JP:4534Mochida Pharmaceutical Co., Ltd.3365.0084.752.58%
JP:4516Nippon Shinyaku Co., Ltd.3302.00-219.85-6.24%

KYORIN Pharmaceutical Co.,Ltd. Corporate Events

KYORIN, Acadia Enter Japan Distribution Agreement for DAYBUE STIX

Nov 16, 2026

KYORIN Pharmaceutical operates in the pharmaceutical industry, with stated activities including developing high-value new drugs and expanding its development pipeline through in-licensing for the Japanese market. It entered an exclusive distribution...

KYORIN Announces Second-Quarter Consolidated Results Release

Nov 9, 2026

KYORIN Pharmaceutical announced its second-quarter consolidated financial results for the fiscal year ending March 31, 2027. The supplied text lists sections covering business performance, financial results, product sales, research and development ex...

KYORIN Gains Japanese Rights to Edesa’s EB05 ARDS Therapy

Nov 9, 2026

KYORIN Pharmaceutical is a Japanese pharmaceutical company that develops and commercializes prescription medicines, particularly treatments addressing unmet medical needs. It has secured exclusive rights in Japan to develop and commercialize Edesa Bi...

KYORIN Reports Mixed Interim Results, Cuts Full-Year Earnings Outlook

Nov 9, 2026

KYORIN Pharmaceutical reported interim net sales of ¥57.489 billion, slightly below its forecast, as sales of Lasvic and Mucodyne underperformed expectations. Operating profit and ordinary profit exceeded forecasts because selling, general and admini...

Kyorin Reports First-Half Net Loss as Profits Decline

Nov 9, 2026

KYORIN Pharmaceutical is a pharmaceutical company; the release does not detail its primary products or specific market focus.For the six months ended September 30, 2026, consolidated sales fell 2.1% year on year to ¥57.489 billion, while operating pr...

Kopernik Global Investors Lifts Stake in KYORIN Pharmaceutical to Over 10%

Oct 28, 2026

KYORIN Pharmaceutical Co., Ltd., a TSE Prime-listed Japanese pharmaceutical manufacturer, develops and markets prescription pharmaceuticals and healthcare-related products. Its shares are held by a mix of domestic and overseas institutional investors...

Kyorin to Divest Generic Drug Unit to New PCPI Platform, Sharpen Focus on New Drugs

Sep 30, 2026

KYORIN Pharmaceutical has signed a definitive agreement to transfer its generic drug business, including subsidiary KYORIN Rimedio and two manufacturing plants, to Pharmatech Co‑creation Platform Inc., a new entity to be jointly established by Daito...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026